Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lifted its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 10.8% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 116,054 shares of the company’s stock after acquiring an additional 11,284 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Mirum Pharmaceuticals were worth $4,526,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Mirum Pharmaceuticals by 7.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,641 shares of the company’s stock worth $448,000 after acquiring an additional 1,246 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Mirum Pharmaceuticals by 11.7% in the first quarter. Russell Investments Group Ltd. now owns 17,481 shares of the company’s stock worth $439,000 after acquiring an additional 1,825 shares in the last quarter. William Blair Investment Management LLC boosted its holdings in Mirum Pharmaceuticals by 0.9% in the first quarter. William Blair Investment Management LLC now owns 627,272 shares of the company’s stock valued at $15,757,000 after purchasing an additional 5,494 shares during the last quarter. Affinity Asset Advisors LLC grew its stake in Mirum Pharmaceuticals by 220.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 160,000 shares of the company’s stock valued at $4,019,000 after purchasing an additional 110,000 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Mirum Pharmaceuticals by 37.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company’s stock worth $40,131,000 after purchasing an additional 432,824 shares during the last quarter.

Wall Street Analysts Forecast Growth

MIRM has been the subject of several research analyst reports. Leerink Partners increased their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Robert W. Baird increased their price objective on shares of Mirum Pharmaceuticals from $39.00 to $44.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Cantor Fitzgerald lifted their target price on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and set a $66.00 price target on shares of Mirum Pharmaceuticals in a research report on Friday, October 11th. Finally, Evercore ISI boosted their price objective on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. Ten analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $56.82.

Mirum Pharmaceuticals Stock Down 3.2 %

Shares of Mirum Pharmaceuticals stock opened at $38.42 on Thursday. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.14 and a 12-month high of $45.23. The firm has a market capitalization of $1.81 billion, a PE ratio of -10.36 and a beta of 1.14. The company has a quick ratio of 3.09, a current ratio of 3.28 and a debt-to-equity ratio of 1.34. The stock’s fifty day moving average is $40.42 and its 200-day moving average is $34.12.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). Mirum Pharmaceuticals had a negative return on equity of 43.47% and a negative net margin of 40.34%. The firm had revenue of $77.90 million during the quarter, compared to analyst estimates of $75.03 million. During the same period in the prior year, the business posted ($0.92) EPS. The company’s revenue for the quarter was up 107.7% on a year-over-year basis. Equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.75 earnings per share for the current year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.